Guadecitabine, also known by its developmental code name SGI-110, is a nucleoside analog and a hypomethylating agent primarily used in the treatment of certain hematological malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Its chemical structure is characterized by the incorporation of a decitabine moiety, which is modified to enhance its stability and bioavailability. Guadecitabine functions by inhibiting DNA methyltransferases, leading to the reactivation of silenced tumor suppressor genes and promoting apoptosis in cancer cells. This compound is administered via subcutaneous injection and has shown promise in clinical trials for its efficacy and safety profile. Its mechanism of action involves the incorporation of the drug into DNA, resulting in the demethylation of cytosine residues, which is crucial for regulating gene expression. As a therapeutic agent, guadecitabine represents a significant advancement in epigenetic therapy, offering a novel approach to treating malignancies that are resistant to conventional therapies.

Guadecitabine

929901-49-5: Guadecitabine, also known by its developmental code name SGI-110, is a nucleoside analog and a hypomethylating agent primarily used in the treatment of certain hematological malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Its chemical structure is characterized by the incorporation of a decitabine moiety, which is modified to enhance its stability and bioavailability. Guadecitabine functions by inhibiting DNA methyltransferases, leading to the reactivation of silenced tumor suppressor genes and promoting apoptosis in cancer cells. This compound is administered via subcutaneous injection and has shown promise in clinical trials for its efficacy and safety profile. Its mechanism of action involves the incorporation of the drug into DNA, resulting in the demethylation of cytosine residues, which is crucial for regulating gene expression. As a therapeutic agent, guadecitabine represents a significant advancement in epigenetic therapy, offering a novel approach to treating malignancies that are resistant to conventional therapies.

<p>Guadecitabine is a second-generation DNA methyltransferases inhibitor. It is used for research on acute myeloid leukemia and myelodysplastic syndromes.</p>

CAS 929901-49-5

Guadecitabine

Guadecitabine

Ref: TM-T16876